Global health company The Cigna Group (NYSE:CI) filed its third quarter 2026 earnings release on November 5, 2026, reporting total revenues of $73.7 billion and adjusted income from operations of $2.1 billion, or $7.98 per share.

Key Highlights

  • Total revenues up 6%: Third quarter 2026 total revenues reached $73.683 billion, compared to $69.748 billion in third quarter 2025.
  • Shareholders' net income: Net income was $1.442 billion, or $5.47 per share, versus $1.868 billion, or $6.98 per share, in third quarter 2025.
  • Adjusted EPS guidance raised: The company increased its 2026 outlook for adjusted income from operations to at least $30.60 per share.
  • Cigna Healthcare pre-tax income rose 15%: Segment adjusted income from operations, pre-tax, increased 15% year over year to $1.193 billion.
  • Share repurchases: Year to date through November 4, 2026, the company repurchased 1.8 million shares of common stock for approximately $500 million.
  • Debt-to-capitalization improved: The ratio fell to 41.8% at September 30, 2026, from 44.9% at September 30, 2025.
  • Long-term targets introduced: At the 2026 Investor Day, the company announced a 10%-14% adjusted EPS CAGR and approximately $50 billion in cumulative operating cash flow through 2030.

Third Quarter 2026 Results Across Evernorth and Cigna Healthcare Segments

According to the filing, The Cigna Group operates through two primary reporting segments: Evernorth Health Services and Cigna Healthcare. Evernorth encompasses Pharmacy Benefit Services, which provides drug claim adjudication, formulary management, and retail pharmacy network administration, as well as Specialty and Care Services, which distributes specialty drugs for complex and rare diseases. Cigna Healthcare covers U.S. commercial medical plans, self-insured client solutions, and international health coverage for globally mobile individuals and multinational organizations.

Evernorth Health Services reported third quarter 2026 adjusted revenues of $63.774 billion, a 6% increase relative to third quarter 2025, the filing disclosed. Within that segment, Pharmacy Benefit Services adjusted revenues rose 9%, driven by drug mix, while adjusted income from operations, pre-tax, decreased 22%, which the filing attributed to large client contract renewals and strategic investments. Specialty and Care Services adjusted income from operations, pre-tax, increased 15%, reflecting strong organic growth including higher biosimilar and specialty generic adoption, which the company said lowers costs for clients and patients.

Cigna Healthcare's adjusted revenues for third quarter 2026 increased 9% to $11.708 billion, with the filing citing premium rate increases to cover expected medical cost increases as the primary driver. The segment's pre-tax adjusted income from operations reached $1.193 billion, up 15% year over year, with higher net investment income and improved operating efficiency credited as contributing factors. The Cigna Healthcare medical cost ratio was reported at 85.0% for the quarter. The filing also noted that in April 2026, the company announced its planned exit from the Individual and Family Plans medical business as of January 1, 2027. Total medical customers across U.S. Healthcare and International Health grew 2% from December 31, 2025 to 18.5 million, reflecting growth in Middle and Select markets.

What Was Disclosed

The Cigna Group disclosed its third quarter 2026 financial results, including segment revenues and earnings, updated full-year adjusted income guidance of at least $30.60 per share, customer relationship counts, share repurchase activity, and long-term financial targets introduced at its 2026 Investor Day.